Shots:

• Moderna has reported the robust results of its ongoing P-I study that demonstrated mRNA-1273 at (25-- 100- & 250-mcg dose levels) induced anti–SARS-CoV-2 immune responses in all participants with no trial-limiting safety concerns. These results were published in NEJM
• All participants seroconverted by the 15-day mark. Post two vaccinations- @57day- geometric mean titers exceeded those seen in convalescent sera obtained from 38 patients with confirmed COVID-19. The mRNA-1273 elicited neutralizing Abs titers- post two vaccination with neutralizing activity against SARS-CoV-2 in all evaluated participants @43day
• Based on P-I interim analysis data- Moderna’s CMO has supported the choice of mRNA-1273 (100mcg) in a prime and boost regimen as the optimal dose for the P-III study scheduled to begin July 27- 2020

Click here to read full press release/ article | Ref: NEJM | Image: Moderna

Related News: Moderna Reports Positive Interim P-I Data of mRNA-1273 Against COVID-19